Global Cell and Gene Therapy Manufacturing QC Market

Focus on Products and Services, Process, Analytical Method, Technology, 17 Countries’ Data and Competitive Landscape - Analysis and Forecast, 2020-2030

Published Year: 2021
SKU: BHP1035SA

5000

Online Access for One Person. Permission to Print

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Product Definition and Market Scope

1.1    Inclusion and Exclusion
1.2    Scope of Work
1.3    Key Questions Answered in the Report

2 Research Methodology

2.1    Primary Data Sources
2.2    Secondary Data Sources
2.3    Market Estimation Model
2.4    Criteria for Company Profiling

3 Market Overview

3.1    Clinical Importance of Cell and Gene Therapies
3.2    Cell and Gene Therapy Manufacturing QC: Industry Overview
3.3    Market Footprint
3.4    Impact of COVID-19

4 Market Dynamics

4.1    Impact Analysis
4.2    Market Drivers
         4.2.1    Increasing Prevalence of Cancer and Chronic Diseases
         4.2.2    Rising Number of Clinical Trials
         4.2.3    Steady Investment and Consolidation in the Cell and Gene Therapy Market
         4.2.4    Favorable Regulatory Environment
4.3    Market Restraints
         4.3.1    Lack of Reliable Vector Production for Cell and Gene Therapy
         4.3.2    Lack of Therapy Specific Assays
4.4    Opportunities
         4.4.1    Drug Approvals and Strong Pipeline of Cell and Gene Therapies
         4.4.2    Multiple Investments in Expansion of cGMP Units

5 Industry Insights

5.1    Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
         5.1.1    Regulatory Challenges
         5.1.2    Successful Regulatory Strategies
5.2    Regulatory Framework
         5.2.1    Chemistry, Manufacturing, and Control (CMC) Requirements by the FDA
                     5.2.1.1    Product Testing
                                    5.2.1.1.1    Microbial Testing
                                    5.2.1.1.2    Identity
                                    5.2.1.1.3    Purity
                                    5.2.1.1.4    Potency
                                    5.2.1.1.5    Viability
                                    5.2.1.1.6    Cell Number/Dose
         5.2.2    Quality Aspects of Cell and Gene Therapy Products by the EMA
                     5.2.2.1    Characterization
                                    5.2.2.1.1    Identity Testing
                                    5.2.2.1.2    Purity Testing
                                    5.2.2.1.3    Potency Testing
                                    5.2.2.1.4    Release Criteria
         5.2.3    Quality Control Requirements for Cell and Gene Therapies in China
                     5.2.3.1    CAR-T Cell Therapy
                     5.2.3.2    Gene Therapy
5.3    Cost Analysis for Cell and Gene Therapy QC

6 Global Cell and Gene Therapy Manufacturing QC Market: Competitive Insights

6.1    Overview
6.2    Synergistic Activities
6.3    Expansion Activities
6.4    Product and Service Launches
6.5    Acquisitions
6.6    Other Developments
6.7    Market Share Analysis, 2019-2020
6.8    Growth Share Analysis
         6.8.1    Growth Share Analysis (by Company)
         6.8.2    Growth Share Analysis (by Technology)
         6.8.3    Growth Share Analysis (by Analytical Method)

7 Global Cell and Gene Therapy Manufacturing QC Market (by Product and Service), $Million, 2019-2030

7.1    Overview
7.2    Service
7.3    Product

8 Global Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2019-2030

8.1    Overview
8.2    Starting Material Preparation
8.3    Upstream Processing
8.4    Downstream Processing

9 Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), $Million, 2019-2030

9.1    Overview
9.2    Safety Testing
9.3    Purity Testing
9.4    Potency Testing
9.5    Identity Testing
9.6    Stability Testing

10 Global Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2019-2030

10.1    Overview
10.2    Polymerase Chain Reaction
10.3    Flow Cytometry
10.4    Limulus Amebocyte Lysate (LAL)
10.5    Enzyme-Linked Immunosorbent Assay (ELISA)
10.6    Chromatography
10.7    Mass Spectrometry
10.8    Western Blotting
10.9    Next-Generation Sequencing
10.10    Electrophoresis
10.11    Other Technologies

11 Global Cell and Gene Therapy Manufacturing QC Market (by Region), $Million, 2019-2030

11.1    Overview
11.2    North America
           11.2.1    U.S.
           11.2.2    Canada
11.3    Europe
           11.3.1    Germany
           11.3.2    U.K.
           11.3.3    France
           11.3.4    Italy
           11.3.5    Spain
           11.3.6    Netherlands
           11.3.7    Russia
           11.3.8    Rest-of-Europe
11.4    Asia-Pacific
           11.4.1    China
           11.4.2    Japan
           11.4.3    South Korea
           11.4.4    Australia
           11.4.5    India
           11.4.6    Singapore
           11.4.7    Rest-of-Asia-Pacific
11.5    Latin America
           11.5.1    Brazil
           11.5.2    Mexico
           11.5.3    Rest-of-Latin America
11.6    Rest-of-the-World (RoW)

12 Company Profiles

12.1    Overview
12.2    bioMérieux SA
           12.2.1    Company Overview
           12.2.2    Role of bioMérieux SA in Global Cell and Gene Therapy Manufacturing QC Market
           12.2.3    Financials
           12.2.4    Key Insights About Financial Health of the Company
           12.2.5    SWOT Analysis
12.3    Bio-Techne Corporation
           12.3.1    Company Overview
           12.3.2    Role of Bio-Techne Corporation in Global Cell and Gene Therapy Manufacturing QC Market
           12.3.3    Financials
           12.3.4    Key Insights About Financial Health of the Company
           12.3.5    SWOT Analysis
12.4    Catalent, Inc.
           12.4.1    Company Overview
           12.4.2    Role of Catalent, Inc. in Global Cell and Gene Therapy Manufacturing QC Market
           12.4.3    Financials
           12.4.4    Key Insights About Financial Health of the Company
           12.4.5    SWOT Analysis
12.5    Charles River Laboratories International Inc.
           12.5.1    Company Overview
           12.5.2    Role of Charles River Laboratories International Inc. in the Global Cell and Gene Therapy Manufacturing QC Market
           12.5.3    Financials
           12.5.4    SWOT Analysis
12.6    Eurofins Scientific SE
           12.6.1    Company Overview
           12.6.2    Role of Eurofins Scientific SE in the Global Cell and Gene Therapy Manufacturing QC Market
           12.6.3    Financials
           12.6.4    SWOT Analysis
12.7    F. Hoffmann-La Roche Ltd
           12.7.1    Company Overview
           12.7.2    Role of F. Hoffmann-La Roche Ltd. in the Global Cell and Gene Therapy Manufacturing QC Market
           12.7.3    Financials
           12.7.4    Key Insights About Financial Health of the Company
           12.7.5    SWOT Analysis
12.8    Intertek Group plc
           12.8.1    Company Overview
           12.8.2    Role of Intertek Group plc in the Global Cell and Gene Therapy Manufacturing QC Market
           12.8.3    Financials
           12.8.4    Key Insights About Financial Health of the Company
           12.8.5    SWOT Analysis
12.9    Lonza Group AG
           12.9.1    Company Overview
           12.9.2    Role of Lonza Group AG in the Global Cell and Gene Therapy Manufacturing QC Market
           12.9.3    Financials
           12.9.4    SWOT Analysis
12.10    Merck KGaA
             12.10.1    Company Overview
             12.10.2    Role of Merck KGaA in the Global Cell and Gene Therapy Manufacturing QC Market
             12.10.3    Financials
             12.10.4    Key Insights About Financial Health of the Company
             12.10.5    SWOT Analysis
12.11    Sartorius AG
             12.11.1    Company Overview
             12.11.2    Role of Sartorius AG in the Global Cell and Gene Therapy Manufacturing QC Market
             12.11.3    Financials
             12.11.4    Key Insights About Financial Health of the Company
             12.11.5    SWOT Analysis
12.12    SGS S.A.
             12.12.1    Company Overview
             12.12.2    Role of SGS S.A. in the Global Cell and Gene Therapy Manufacturing QC Market
             12.12.3    Financials
             12.12.4    SWOT Analysis
12.13    Sistemic Scotland Limited
             12.13.1    Company Overview
             12.13.2    Role of Sistemic Scotland Limited in Global Cell and Gene Therapy Manufacturing QC Market
             12.13.3    SWOT Analysis
12.14    Thermo Fisher Scientific Inc.
             12.14.1    Company Overview
             12.14.2    Role of Thermo Fisher Scientific Inc. in the Global Cell and Gene Therapy Manufacturing QC Market
             12.14.3    Financials
             12.14.4    Key Insights About Financial Health of the Company
             12.14.5    SWOT Analysis
12.15    Vigene Biosciences, Inc.
             12.15.1    Company Overview
             12.15.2    Role of Vigene Biosciences, Inc. in Global Cell and Gene Therapy Manufacturing QC Market
             12.15.3    SWOT Analysis
12.16    WuXi AppTec
             12.16.1    Company Overview
             12.16.2    Role of WuXi AppTec in Global Cell and Gene Therapy Manufacturing QC Market
             12.16.3    Financials
             12.16.4    SWOT Analysis

List of Tables

Table 3.1:    Key Products of Cell and Gene Therapy Market
Table 4.1:    Impact Analysis
Table 4.2:    Key Cell and Gene Therapies with FDA Expedited Review
Table 5.1:    Product Class Inclusions in EU and U.S. Regulatory Pathway
Table 7.1:    List of Key Services
Table 7.2:    List of Key Products Offered
Table 9.1:    Key Safety Testing Offerings
Table 9.2:    Key Purity Testing Offerings
Table 9.3:    Key Potency Testing Offerings
Table 9.4:    Key Identity Testing Offerings
Table 9.5:    Key Stability Testing Offerings
Table 10.1:    Key PCR-Based Offerings
Table 10.2:    Key Flow Cytometry-Based Offerings
Table 10.3:    Key LAL-Based Offerings
Table 10.4:    Key ELISA-Based Offerings
Table 10.5:    Key Chromatography-Based Offerings
Table 10.6:    Key Mass Spectrometry-Based Offerings
Table 10.7:    Key Western Blotting-Based Offerings
Table 10.8:    Key NGS-Based Offerings
Table 10.9:    Key Electrophoresis-Based Offerings

List of Figures

Figure 1:    Global Clinical Landscape for Regenerative Medicine, 2019
Figure 2:    Impact Analysis on the Global Cell and Gene Therapy Manufacturing QC Market
Figure 3:    Global Cell and Gene Therapy Manufacturing QC Market (by Product and Service), $Million, 2019 and 2030
Figure 4:    Global Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2019 and 2030
Figure 5:    Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), $Million, 2019 and 2030
Figure 6:    Global Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2019 and 2030
Figure 7:    Global Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
Figure 1.1:    Global Cell and Gene Therapy Manufacturing QC Market Segmentation Primary Research Methodology
Figure 2.1:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2:    Top-Down Approach (Segment-Wise Analysis)
Figure 3.1:    Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2019
Figure 3.2:    Global Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 3.3:    Impact of COVID-19 on Global Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 4.1:    Number of Clinical Trials for ATMP (by Phase), 2019
Figure 5.1:    Cost of Manufacturing Cell Therapies
Figure 6.1:    Share of Key Developments and Strategies, January 2018-Januray 2021
Figure 6.2:    Synergistic Activities Share (by Company), January 2018-January 2021
Figure 6.3:    Expansion Activities Share (by Company), January 2018-January 2021
Figure 6.4:    Product and Services Launches Share (by Company), January 2018- January 2021
Figure 6.5:    Product and Services Launches Share (by Company), January 2018- January 2021
Figure 6.6:    Market Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market, 2019 and 2020
Figure 6.7:    Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Company), 2020
Figure 6.8:    Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Technology), 2019-2030
Figure 6.9:    Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), 2019-2030
Figure 7.1:    Global Cell and Gene Therapy Manufacturing QC Market (by Product and Service), $Million, 2019 and 2030
Figure 7.2:    Global Cell and Gene Therapy Manufacturing QC Market (by Service), $Million, 2019-2030
Figure 7.3:    Global Cell and Gene Therapy Manufacturing QC Market (by Product), $Million, 2019-2030
Figure 7.4:    Global Cell and Gene Therapy Manufacturing QC Market (by Product), $Million, 2019 and 2030
Figure 8.1:    Global Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2019 and 2030
Figure 8.2:    Global Cell and Gene Therapy Manufacturing QC Market (by Starting Material Preparation), $Million, 2019-2030
Figure 8.3:    Global Cell and Gene Therapy Manufacturing QC Market (by Upstream Processing), $Million, 2019-2030
Figure 8.4:    Global Cell and Gene Therapy Manufacturing QC Market (by Downstream Processing), $Million, 2019-2030
Figure 9.1:    Product Characterization Tests for Cell and Gene Therapy Manufacturing
Figure 9.2:    Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), $Million, 2019 and 2030
Figure 9.3:    Global Cell and Gene Therapy Manufacturing QC Market (by Safety Testing), $Million, 2019-2030
Figure 9.4:    Global Cell and Gene Therapy Manufacturing QC Market (by Safety Testing Type), $Million, 2019 and 2030
Figure 9.5:    Global Cell and Gene Therapy Manufacturing QC Market (by Purity Testing), $Million, 2019-2030
Figure 9.6:    Global Cell and Gene Therapy Manufacturing QC Market (by Purity Testing Type), $Million, 2019 and 2030
Figure 9.7:    Global Cell and Gene Therapy Manufacturing QC Market (by Potency Testing), $Million, 2019-2030
Figure 9.8:    Global Cell and Gene Therapy Manufacturing QC Market (by Potency Testing Type), $Million, 2019 and 2030
Figure 9.9:    Global Cell and Gene Therapy Manufacturing QC Market (by Identity Testing), $Million, 2019-2030
Figure 9.10: Global Cell and Gene Therapy Manufacturing QC Market (by Stability Testing), $Million, 2019-2030    
Figure 9.11: Global Cell and Gene Therapy Manufacturing QC Market (by Stability Testing Type), $Million, 2019 and 2030    
Figure 10.1:    Global Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2019 and 2030
Figure 10.2:    Global Cell and Gene Therapy Manufacturing QC Market (PCR), $Million, 2019-2030
Figure 10.3:    Global Cell and Gene Therapy Manufacturing QC Market (Flow Cytometry), $Million, 2019-2030
Figure 10.4:    Global Cell and Gene Therapy Manufacturing QC Market (LAL), $Million, 2019-2030
Figure 10.5:    Global Cell and Gene Therapy Manufacturing QC Market (ELISA), $Million, 2019-2030
Figure 10.6:    Global Cell and Gene Therapy Manufacturing QC Market (Chromatography), $Million, 2019-2030
Figure 10.7:    Global Cell and Gene Therapy Manufacturing QC Market (Mass Spectrometry), $Million, 2019-2030
Figure 10.8:    Global Cell and Gene Therapy Manufacturing QC Market (Western Blotting), $Million, 2019-2030
Figure 10.9:    Global Cell and Gene Therapy Manufacturing QC Market (NGS), $Million, 2019-2030
Figure 10.10:    Global Cell and Gene Therapy Manufacturing QC Market (Electrophoresis), $Million, 2019-2030
Figure 10.11:    Global Cell and Gene Therapy Manufacturing QC Market (Other Technologies), $Million, 2019-2030
Figure 11.1:    Global Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
Figure 11.2:    North America: Market Dynamics
Figure 11.3:    North America Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.4:    North America Cell and Gene Therapy Manufacturing QC Market (by Country), $Million, 2019 vs. 2030
Figure 11.5:    U.S. Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.6:    Canada Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.7:    Europe: Market Dynamics
Figure 11.8:    Europe Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.9:    Europe Cell and Gene Therapy Manufacturing QC Market (by Country), $Million, 2019 vs. 2030
Figure 11.10:    Germany Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.11:    U.K. Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.12:    France Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.13:    Italy Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.14:    Spain Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.15:    Netherlands Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.16:    Russia Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.17:    Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.18:    Asia-Pacific: Market Dynamics
Figure 11.19:    Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.20:    Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), $Million, 2019 vs. 2030
Figure 11.21:    China Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.22:    Japan Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.23:    South Korea Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.24:    Australia Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.25:    Italy Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.26:    Singapore Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.27:    Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.28:    Latin America: Market Dynamics
Figure 11.29:    Latin America Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.30:    Latin America Cell and Gene Therapy Manufacturing QC Market (by Country), $Million, 2019 vs. 2030
Figure 11.31:    Brazil Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.32:    Mexico Cell and Gene Therapy Manufacturing QC Market, $Million,  2019-2030
Figure 11.33:    Rest-of-Latin America Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 11.34:    Rest-of-the-World Cell and Gene Therapy Manufacturing QC Market, $Million, 2019-2030
Figure 12.1:    Total Number of Companies Profiled
Figure 12.2:    bioMérieux SA: Overall Product Portfolio
Figure 12.3:    bioMérieux SA: Overall Financials, 2017-2019
Figure 12.4:    bioMérieux SA: Revenue (by Segment), 2017-2019
Figure 12.5:    bioMérieux SA: Revenue (by Region), 2017-2019
Figure 12.6:    bioMérieux SA: R&D Expenditure, 2017-2019
Figure 12.7:    bioMérieux SA: SWOT Analysis
Figure 12.8:    Bio-Techne Corporation: Overall Product Portfolio
Figure 12.9:    Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 12.10:    Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 12.11:    Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 12.12:    Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 12.13:    Bio-Techne Corporation: SWOT Analysis
Figure 12.14:    Catalent, Inc.: Overall Product Portfolio
Figure 12.15:    Catalent, Inc.: Overall Financials, 2018-2020
Figure 12.16:    Catalent, Inc.: Revenue (by Segment), 2018-2020
Figure 12.17:    Catalent, Inc.: Revenue (by Region), 2018-2020
Figure 12.18:    Catalent, Inc.: R&D Expenditure, 2018-2020
Figure 12.19:    Catalent, Inc.: SWOT Analysis
Figure 12.20:    Charles River Laboratories International Inc.: Overall Service Portfolio
Figure 12.21:    Charles River Laboratories International Inc.: Overall Financials,  2017-2019
Figure 12.22:    Charles River Laboratories International Inc.: Revenue (by Segment), 2017-2019
Figure 12.23:    Charles River Laboratories International Inc.: Revenue (by Region),  2017-2019
Figure 12.24:    Charles River Laboratories International Inc.: SWOT Analysis
Figure 12.25:    Eurofins Scientific SE: Service Portfolio
Figure 12.26:    Eurofins Scientific SE: Overall Financials, 2017-2019
Figure 12.27:    Eurofins Scientific SE: Revenue (by Segment), 2018-2019
Figure 12.28:    Eurofins Scientific SE: Revenue (by Region), 2017-2019
Figure 12.29:    Eurofins Scientific SE.: SWOT Analysis
Figure 12.30:    F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
Figure 12.31:    F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
Figure 12.32:    F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
Figure 12.33:    F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics), 2018-2020
Figure 12.34:    F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
Figure 12.35:    F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 12.36:    F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.37:    Intertek Group plc: Overall Product Portfolio
Figure 12.38:    Intertek Group plc: Overall Financials, 2017-2019
Figure 12.39:    Intertek Group plc: Revenue (by Segment), 2017-2019
Figure 12.40:    Intertek Group plc: Revenue (by Region), 2017-2019
Figure 12.41:    Intertek Group plc: R&D Expenditure, 2017-2019
Figure 12.42:    Intertek Group plc: SWOT Analysis
Figure 12.43:    Lonza Group AG: Overall Product Portfolio
Figure 12.44:    Lonza Group AG: Overall Financials, 2018-2020
Figure 12.45:    Lonza Group AG: Revenue (by Segment), 2018-2020
Figure 12.46:    Lonza Group AG: Revenue (by Region), 2018-2020
Figure 12.47:    Lonza AG: SWOT Analysis
Figure 12.48:    Merck KGaA: Overall Product Portfolio
Figure 12.49:    Merck KGaA: Overall Financials, 2017-2019
Figure 12.50:    Merck KGaA: Revenue (by Segment), 2017-2019
Figure 12.51:    Merck KGaA: Revenue (by Region), 2017-2019
Figure 12.52:    Merck KGaA: R&D Expenditure, 2017-2019
Figure 12.53:    Merck KGaA: SWOT Analysis
Figure 12.54:    Sartorius AG: Overall Product Portfolio
Figure 12.55:    Sartorius AG: Overall Financials, 2017-2019
Figure 12.56:    Sartorius AG: Revenue (by Segment), 2017-2019
Figure 12.57:    Sartorius AG: Revenue (by Region), 2017-2019
Figure 12.58:    Sartorius AG: R&D Expenditure, 2017-2019
Figure 12.59:    Sartorius AG: SWOT Analysis
Figure 12.60:    SGS S.A.: Overall Product Portfolio
Figure 12.61:    SGS S.A.: Overall Financials, 2018-2020
Figure 12.62:    SGS S.A.: Revenue (by Segment), 2018-2020
Figure 12.63:    SGS S.A.: Revenue (by Region), 2018-2020
Figure 12.64:    SGS S.A.: SWOT Analysis
Figure 12.65:    Sistemic Scotland Limited: Portfolio
Figure 12.66:    Sistemic Scotland Limited: SWOT Analysis
Figure 12.67:    Thermo Fisher Scientific Inc.: Product Portfolio
Figure 12.68:    Thermo Fisher Scientific Inc.: Overall Financials: 2017-2019
Figure 12.69:    Thermo Fisher Scientific Inc.: Sales (by Segment): 2017-2020
Figure 12.70:    Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 12.71:    Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 12.72:    Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 12.73:    Vigene Biosciences, Inc.: Portfolio
Figure 12.74:    Vigene Biosciences, Inc.: SWOT Analysis
Figure 12.75:    WuXi AppTec: Product Portfolio
Figure 12.76:    WuXi AppTec: Overall Financials, 2017-2019
Figure 12.77:    WuXi AppTec: Sales (by Segment), 2017-2019
Figure 12.78:    WuXi AppTec: Revenue (by Region), 2017-2019
Figure 12.79:    WuXi AppTec: SWOT Analysis

FAQ's

Q. What is the estimated growth rate for cell and gene therapy manufacturing QC market in the coming years?

The cell and gene therapy manufacturing QC market is estimated to grow at a CAGR of 22.80% during the forecast period from 2020 to 2030.

Q. What are the possible challenges that can restrict the growth of the cell and gene therapy manufacturing QC market?

Factors responsible for restraining the growth of the market include lack of reliable vector production for cell and gene therapy and lack of therapy specific assays.

Q. What are the different process types of cell and gene therapy manufacturing QC market?

The processes covered under cell and gene therapy manufacturing QC market include starting material preparation, upstream processing, and downstream processing.

Q. What are the different analytical methods covered under the cell and gene therapy manufacturing QC market?

The different analytical methods covered under the market include safety testing, purity testing, potency testing, identity testing, and stability testing.

Q. Which are the top market players operating in the cell and gene therapy manufacturing QC market?

The key players operating in the market bioMérieux SA, Bio-Techne Corporation, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A, Thermo Fisher Scientific Inc., WuXi AppTec, Sistemic Scotland Limited, and Vigene Biosciences, Inc.

You may also like

Published Year: 2021

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is...

 
Published Year: 2021

Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Coun

The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to...

 
Published Year: 2020

Global Next-Generation Biomanufacturing Market – Analysis and Forecast, 2019-2029: Focus on Workfl

The Global Next-Generation Biomanufacturing Market Report by BIS Research projects the market...

 
Published Year: 2019

Global Industrial Microbiological QC Market: Focus on Technology Trends, Application, Regulatory Fra

The global industrial microbiological QC market is expected to continue to grow with a single...

 
Published Year: 2017

Global Industrial Microbiology Market - Analysis and Forecast (2017-2025): (Focus on Competitive Lan

The pharmaceuticals and biotechnology as well as food and beverages industry are the largest...

 

Global Cell and Gene Therapy Manufacturing QC Market

Focus on Products and Services, Process, Analytical Method, Technology, 17 Countries’ Data and Competitive Landscape - Analysis and Forecast, 2020-2030